Boehringer Ingelheim is paying 1.18 billion euros ($1.5 billion) for Swiss-based NBE Therapeutics as the German drugmaker is adding pipeline candidates including a drug in early trials against triple-negative breast cancer and lung cancer.
BioSpace Global Roundup: Ipsen Wins Fast Track Designation for Cancer Drug and More
3D, Antibody-Drug Conjugates (ADCs), Business, Clinical Trials, Collaborations, Coronavirus Disease 2019 (COVID-19), Data, E. Coli, Fast Track Designation, FDA, Gene Editing, Joint Ventures, Licensing, Metastatic pancreatic cancer, Neurological Disorders, R&D, Series A, Small cell lung cancer, Staphylococcus aureus infections, Therapeutics, Ulcerative Colitis, VaccinesParis-based Ipsen secured Fast Track designation from the U.S. Food and Drug Administration for Onivyde (irinotecan liposome injection) for study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen.
Urovant’s Irritable Bowel Drug Fails in Phase II; Genmab Abandons Cancer Drug
Abdominal Pain, Antibody-Drug Conjugates (ADCs), Biomarkers, Business, Cancer, Clinical Trials, Irritable Bowel Syndrome with Diarrhea (IBS-D), Monoclonal Antibodies, Product Pipelines, R&D, Shares, Small Molecules, Solid Tumors, Topline DataUrovant Sciences and Genmab reported disappointing clinical trial announcements.
ADC Therapeutics SA announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for loncastuximab tesirine (Lonca) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Immunomedics drug Trodelvy extends survival in breast cancer patients
Accelerated Approval, Antibody-Drug Conjugates (ADCs), Boxed Warning, Business, Cancer Cells, Clinical Trials, Deals, European Society for Medical Oncology (ESMO), FDA, Metastatic Triple-Negative Breast Cancer (mTNBC), R&D, TherapeuticsImmunomedics Inc.’s cancer drug Trodelvy, which received accelerated U.S. regulatory approval in April 2020, extended survival time in previously treated patients with an advanced form of breast cancer in a clinical trial.
Merck and Seattle Genetics Ink Two New Strategic Cancer Collaborations
Antibody-Drug Conjugates (ADCs), Blockbusters, Business, Cancer, Checkpoint Inhibitors, Clinical Trials, Collaborations, Deals, HER2 protein, Investments, Licensing, Oncology, Premarket Trading, R&D, Small Molecules, Solid Tumors, Triple Negative Breast Cancer (TNBC), Tyrosine kinase inhibitorsSeattle Genetics’ shares rocketed after news broke of Merck making a major investment into the Bothwell, Washington-based company via two strategic oncology deals.
Gilead Sciences Inc. and Immunomedics announced that the companies entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share in cash.
AstraZeneca inked a global development and commercialization deal with Daiichi Sankyo for DS-1062, a trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate for multiple cancer types.
GSK’s blood cancer drug wins European panel thumbs-up
Antibody-Drug Conjugates (ADCs), B-cell maturation antigen (BCMA), Blockbusters, Blood Cancers, Cells, Chemotherapy, European Medicines Agency, FDA/Regulatory, Immunomodulatory Agents, Recommended For Approval, Relapse/Refractory Multiple MyelomaA panel of the European Medicines Agency recommended approving GlaxoSmithKline’s experimental treatment for a common form of blood cancer, days after a similar nod from a U.S. Food and Drug Administration panel.
An independent panel to the U.S. Food and Drug Administration voted in favor of approving GlaxoSmithKline’s experimental treatment for a common form of blood cancer, saying the benefits of the treatment outweigh the risks.